MD‐7246, a Delayed‐Release Formulation of Linaclotide Targeting Visceral Pain Associated With IBS‐D, Does Not Impact Bowel Frequency or Stool Consistency in Healthy Volunteers: Results From Phase I Trial: 497. (October 2019)